As the US prepares for the release of final guidelines in making biosimilars more available to the public, policy officials and decision-makers have the opportunity to learn from the European Union’s experience on the subject. Biosimilars have been around in the EU for nearly a decade, and many of the complications and discussions about biosimilars in the US can be improved and fast-tracked by following European models of testing, naming, guidelines, and interchangeability. To fully understand how the future of biosimilars in the US will benefit from the existing framework in Europe, consider how today’s biosimilar market in the US compares to the history and marketability of biosimilars in Europe.Read More
CBI Scene Blog
The Need for Adaptability
Marketing in the healthcare field today is anything but a static environment. Every pharmaceutical brand is daily forced to deal with a constantly changing environment in the areas of technology, regulatory issues, and client expectations. In addition to flexibility, efforts to engage healthcare professionals require high levels of creativity and constant adaption.
Topics: Brand & Digital Strategy